Terms: = Lung cancer AND RAD51B, ENSG00000182185, 5890, RAD51L1, O15315, hREC2, R51H2, REC2, MGC34245 AND Treatment
4 results:
1. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract] [Full Text] [Related]
2. Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer.
Leiser D; Samanta S; Eley J; Strauss J; Creed M; Kingsbury T; Staats PN; Bhandary B; Chen M; Dukic T; Roy S; Mahmood J; Vujaskovic Z; Shukla HD
PLoS One; 2021; 16(11):e0258951. PubMed ID: 34762666
[TBL] [Abstract] [Full Text] [Related]
3. Methylation of rad51b, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.
Rieke DT; Ochsenreither S; Klinghammer K; Seiwert TY; Klauschen F; Tinhofer I; Keilholz U
Oncotarget; 2016 Nov; 7(46):75379-75393. PubMed ID: 27683114
[TBL] [Abstract] [Full Text] [Related]
4. ERCC1 expression and rad51b activity correlate with cell cycle response to platinum drug treatment not DNA repair.
Stordal B; Davey R
Cancer Chemother Pharmacol; 2009 Mar; 63(4):661-72. PubMed ID: 18575867
[TBL] [Abstract] [Full Text] [Related]
